Daiichi Sankyo Company, Limited announced senior-level organizational changes to oversee the realization of the company's long-term vision and strategic priorities, which include delivering seven distinct new molecular entities in oncology by 2025, as well as specialty medicines that change the standard of care. Junichi Koga, PhD will become the new global Head of R&D Unit, drawing from his deep expertise in bioengineering and biologics research and development. Dr. Koga, currently Senior Executive Officer and Head of the R&D Division in Japan, will assume his new role on April 1, 2019 and will relocate to the company's U.S. site in Basking Ridge, New Jersey. He will co-chair the Daiichi Sankyo Global Executive Meeting of Research and Development (GEMRAD) together with Antoine Yver, MD, the Head of Oncology R&D. Glenn Gormley, will complete his term as global Head of R&D Unit, Senior Executive Officer of Daiichi Sankyo Company, Limited and President and CEO of Daiichi Sankyo Inc. (the company's U.S. affiliate) on March 31, 2019. He will remain at the company as Chairman of the Board of Directors of Daiichi Sankyo Inc. and serve as a special advisor to the company's global Chief Executive Officer Joji Nakayama on R&D matters. Also on April 1, 2019, Ken Keller, currently President of Daiichi Sankyo Administrative and Commercial at Daiichi Sankyo Inc., will take on the expanded role of President and CEO, Daiichi Sankyo Inc. and will focus on forging even stronger collaboration between R&D and commercial efforts, along with enhancing the company's patient-focused culture. Mr. Keller will also remain in his current role as President & CEO of American Regent Inc.